Lamivudine and Entecavir for Acute Hepatitis B: A Systematic Review and Meta-Analysis

Lamivudine and Entecavir for Acute Hepatitis B: A Systematic Review and Meta-Analysis

Background. Acute hepatitis B infection is associated with severe liver disease and chronic sequelae in some cases. The purpose of this review was to determine the efficacy of nucleoside analogues (NA) (lamivudine versus entecavir) compared to placebo or no intervention for treating acute primary HB...

Full description

Bibliographic Details
Main Authors:	Cesar Henriquez-Camacho, Ana Isabel Hijas-Gomez, Carlos Risco Risco, Maria Angeles Ruiz Lapuente, Rosa Escudero-Sanchez, Victor Moreno Cuerda
Format:	Article
Language:	English
Published:	MDPI AG 2023-11-01
Series:	Viruses
Subjects:	nucleoside analogue lamivudine entecavir acute Hepatitis B viral hepatitis
Online Access:	https://www.mdpi.com/1999-4915/15/11/2241

Similar Items

Impact of prior lamivudine use on the antiviral efficacy and development of resistance to entecavir in chronic hepatitis B patients
by: Joo An Hwang, et al.
Published: (2015-06-01)

Efficacy of tenofovir-based rescue therapy for chronic hepatitis B patients with resistance to lamivudine and entecavir
by: Hee-Jeong Jeon, et al.
Published: (2017-09-01)

Long-term outcomes of two rescue therapies in lamivudine-refractory patients with chronic hepatitis B: combined lamivudine and adefovir, and 1-mg entecavir
by: EunYoung Ze, et al.
Published: (2014-09-01)

Analysis of minimum target prices for production of entecavir to treat hepatitis B in high- and low-income countries
by: Andrew Hill, et al.
Published: (2015-04-01)

Unsuccessful therapy with adefovir and entecavir-tenofovir in a patient with chronic hepatitis B infection with previous resistance to lamivudine: a fourteen-year evolution of hepatitis B virus mutations
by: Tanno Hugo, et al.
Published: (2011-06-01)

Entecavir plus tenofovir versus entecavir plus adefovir in chronic hepatitis B patients with a suboptimal response to lamivudine and adefovir combination therapy
by: Jung Gil Park, et al.
Published: (2015-09-01)

Lamivudine plus adefovir combination therapy versus entecavir monotherapy for lamivudine-resistant chronic hepatitis B: a systematic review and meta-analysis
by: Hu Peng, et al.
Published: (2011-08-01)

Efficacy and safety of entecavir versus lamivudine over 5 years of treatment: A randomized controlled trial in Korean patients with hepatitis B e antigen-negative chronic hepatitis B
by: Kwan Sik Lee, et al.
Published: (2017-12-01)

Lamivudine switch therapy in chronic hepatitis B patients achieving undetectable hepatitis B virus DNA after 3 years of entecavir therapy: A prospective, open-label, multicenter study
by: Ming-Lun Yeh, et al.
Published: (2016-11-01)

Lamivudine: fading into the mists of time
by: Jonggi Choi, et al.
Published: (2017-12-01)

Is it possible to predict the development of an entecavir resistance mutation in patients with chronic hepatitis B in clinical practice?
by: Joon Yeul Nam, et al.
Published: (2017-12-01)

Laboratory Evaluation of Three Regimens of Treatment of Chronic Hepatitis B: Tenofovir, Entecavir and Combination of Lamivudine and Adefovir
by: Rajeswari Jayakumar, et al.
Published: (2012-01-01)

Entecavir+tenofovir vs. lamivudine/telbivudine+adefovir in chronic hepatitis B patients with prior suboptimal response
by: Hyun Young Woo, et al.
Published: (2020-07-01)

The efficacy of tenofovir-based therapy in patients showing suboptimal response to entecavir-adefovir combination therapy
by: Jeong Han Kim, et al.
Published: (2016-06-01)

EFFECTIVE PREVENTION AND TREATMENT OF CHRONIC HEPATITIS B IN THE CONTEMPORARY PRACTICE OF HEPATOLOGY
by: R. G. MYAZIN
Published: (2017-05-01)

Antiviral efficacy of entecavir for hepatitis B virus rtA181V/T mutants
by: Ping Li, et al.
Published: (2017-04-01)

Lamivudine for chronic hepatitis B: a brief review
by: Emilio Palumbo

Comparison of entecavir and adefovir for the treatment of chronic hepatitis B
by: Si-Hai Zhao, et al.

Entecavir Treatment in Children and Adolescents with Chronic Hepatitis B Virus Infection
by: Kai-Chi Chang, et al.
Published: (2016-10-01)

Off-treatment efficacy of 3-year nucleos(t)ide analogues in chronic hepatitis B patients
by: Ching-Chung Lin, et al.
Published: (2016-01-01)

Lamivudine therapy for hepatitis B in renal transplantation
by: F.R.L. Santos, et al.
Published: (2002-02-01)

Hepatitis B virus mutation pattern rtL180M+A181C+M204V may contribute to entecavir resistance in clinical practice
by: Yan Liu, et al.
Published: (2019-01-01)

Efficacy and safety of entecavir plus carnitine complex (GODEX®) compared to entecavir monotherapy in patient with ALT elevated chronic hepatitis B: randomized, multicenter open-label trials. The GOAL study
by: Dae Won Jun, et al.
Published: (2013-06-01)

Treatment of chronic hepatitis B in Oman experience with lamivudine
by: Upadhyay Dip Amal, et al.
Published: (2003-01-01)

Severe Acute Hepatitis B Treated with Entecavir
by: Andrea Tosti, et al.
Published: (2011-01-01)

A Case of Severe Peripheral Polyneuropathy Occurring after Entecavir Treatment in a Hepatitis B Patient
by: Ji Hyun Song, et al.
Published: (2016-04-01)

Long-term entecavir efficacy retention in the treatment of chronic hepatitis B with an outcome to hepatic cirrhosis caused by its resistant virus strain
by: O O Znoĭko, et al.
Published: (2012-11-01)

HBV Reactivation and Lamivudine Treatment in Patients with Lymphoma Undergoing Chemotherapy: Four Cases
by: İlhan AFŞAR, et al.
Published: (2006-12-01)

Lamivudine therapy for chronic hepatitis B in children: a meta-analysis
by: Aoran Luo, et al.
Published: (2019-07-01)

Acute pancreatitis associated with lamivudine therapy for chronic B hepatitis
by: Felipe Francisco Tuon, et al.

Comparison of tenofovir plus lamivudine versus tenofovir monotherapy in patients with lamivudine-resistant chronic hepatitis B
by: Chan Ho Park, et al.
Published: (2016-03-01)

Evaluation of the Efficacy of Entecavir and Tenofovir in the Treatment of Chronic Hepatitis B: A Retrospective Study
by: Arzu ŞENOL, et al.
Published: (2019-12-01)

Selected ginsenosides interfere efficiently with hepatitis B virus mRNA expression levels and suppress viral surface antigen secretion
by: Ganesh Selvaraj Duraisamy, et al.
Published: (2022-09-01)

THE EXPERIENCE OF ENTECAVIR USE IN PATIENTS WITH HEPATITIS B VIRAL INFECTION ON AN OUTPATIENT BASIS
by: L. I. Mel'nikova, et al.
Published: (2016-02-01)

Experience with lamivudine treatment for severe acute hepatitis B
by: Verhaz Antonija
Published: (2014-01-01)

Seroconversion of hepatitis B envelope antigen (HBeAg) by entecavir in a child with chronic hepatitis B
by: Mohammed Y Hasosah, et al.
Published: (2012-01-01)

Comparison of first-year results of tenofovir and entecavir treatments of nucleos(t)ide-naive chronic hepatitis B patients with hepatosteatosis
by: Zeynal Dogan, et al.
Published: (2015-01-01)

Efficacy of prolonged entecavir monotherapy in treatment-naïve chronic hepatitis B patients exhibiting a partial virologic response to entecavir
by: Han Na Choi, et al.
Published: (2015-03-01)

Entecavir in the treatment of chronic hepatitis B: multicenter randomized trials and real clinical practice
by: D T Abdurakhmanov, et al.
Published: (2014-11-01)

The effects of prolonged Lamivudine administration as a sole treatment following the combination therapy of Interferon Alpha and Lamivudine in children for HBeAg (+) chronic hepatitis B
by: Sezin Asik Akman,1 Sabriye Cokceken Okcu,2 Sumer Sutcuoglu.2
Published: (2007-10-01)